Caldera Medical Unveils Three New Urinary Incontinence Products

Caldera Medical has debuted three U.S. Food and Drug Administration-cleared products that treat female stress urinary incontinence: Desara Mini, Desara SL, and Desara Blue.

Desara Blue is a blue version of Caldera Medical’s Desara universal sling system and provides surgeons with their choice of multiple surgical approaches by utilizing reusable instrumentation. The blue color provides exceptional visibility both during and after the procedure, the company claims.

Desara SL utilizes the same Desara mesh in a shorter 12-centimeter length to minimize the amount of mesh implanted. A shorter 12 cm sling length has been shown to significantly reduce post-operative groin pain, making patients more comfortable while delivering equivalent safety and efficacy as traditional slings.

Desara Mini is a mini sling which combines the Desara mesh with a secure fixation system that allows for sling placement in a less invasive, single incision procedure.

“The addition of three new products for the treatment of SUI in 2013, Desara Mini, Desara SL, and Desara Blue, demonstrates our continued commitment to providing our physician customers with a line of solutions for the treatment of stress urinary incontinence,” Bryon L. Merade, Chairman and CEO said.

Caldera Medical’s other product lines include the Desara Sling System for treatment of stress urinary incontinence and Vertessa Lite, a supple, lightweight yet strong polypropylene mesh used in abdominal sacrocolpopexy procedures to treat pelvic organ prolapse (POP). Stress urinary incontinence, the most prevalent form of incontinence among women, affects an estimated 15 million adult women in the United States and incontinence is the second leading cause of institutionalization in older women, industry data show.

Pelvic organ prolapse is one of the most common quality of life conditions facing women, with nearly 50 percent  of all women who give birth vaginally developing POP, according to Caldera. A woman’s lifetime probability for undergoing a surgical treatment to correct POP is approximately 11 percent. Abdominal sacrocolpopexy procedures are expected to grow approximately 15 percent in 2013 due to a shift from transvaginal prolapse repair procedures.

Headquartered in Agoura Hills, Calif., Caldera Medical develops and markets differentiated surgical implants specifically for the treatment of stress urinary incontinence and POP across the gynecology, urology and urogynecology specialties.